{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:22:29Z","timestamp":1778548949886,"version":"3.51.4"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Intrahepatic cholangiocarcinoma is a malignant tumor that starts from the epithelium of the bile duct and has a poor prognosis. They are characterized by poor response to chemotherapy and lack of effective targeted therapies; thus, therapeutic options are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Presentation<\/jats:title>\n                  <jats:p>A 59-year-old man was admitted to the hospital for a workup of abnormal CA19-9 levels. He was diagnosed with ICC, underwent surgery and was found to have pT1bNx disease. He developed rapid disease recurrence on adjuvant gemcitabine + capecitabine. Following recurrence, he received first-line systemic pembrolizumab + lenvatinib and second-line pembrolizumab + lenvatinib + chemotherapy and had mild tumor regression followed by progression. Next-generation sequencing was performed on the baseline surgical sample. This revealed a novel RBPMS-MET fusion, and based on the literature, crizotinib 250\u00a0mg twice a day was administered. After 3 months of crizotinib treatment, magnetic resonance imaging revealed a significant reduction in liver lesions, and 4 months after initiating treatment, scans demonstrated a partial response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our case report strengthens the evidence that crizotinib may be a viable treatment option for patients with ICC with a c-MET tyrosine kinase fusion, necessitating additional clinical investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae340","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T02:06:42Z","timestamp":1733882802000},"source":"Crossref","is-referenced-by-count":4,"title":["Precision medicine: an intrahepatic cholangiocarcinoma with a novel RBPMS-MET fusion sensitive to crizotinib"],"prefix":"10.1093","volume":"30","author":[{"given":"Wei","family":"Wan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Xi\u2019an International Medical Center , Shaanxi, Xi\u2019an, 710100 ,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Xi\u2019an International Medical Center , Shaanxi, Xi\u2019an, 710100 ,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Xi\u2019an International Medical Center , Shaanxi, Xi\u2019an, 710100 ,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Xi\u2019an International Medical Center , Shaanxi, Xi\u2019an, 710100 ,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihu","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Xi\u2019an International Medical Center , Shaanxi, Xi\u2019an, 710100 ,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangni","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Xi\u2019an International Medical Center , Shaanxi, Xi\u2019an, 710100 ,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Tan","sequence":"additional","affiliation":[{"name":"The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd , Nanjing, 210018 ,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Duan","sequence":"additional","affiliation":[{"name":"The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd , Nanjing, 210018 ,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinpeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Xi\u2019an International Medical Center , Shaanxi, Xi\u2019an, 710100 ,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6791-2050","authenticated-orcid":false,"given":"Wuping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Xi\u2019an International Medical Center , Shaanxi, Xi\u2019an, 710100 ,\u00a0","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"2025031509021345400_CIT0001","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2025031509021345400_CIT0002","doi-asserted-by":"publisher","first-page":"e1187","DOI":"10.1097\/SLA.0000000000003788","article-title":"Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis","volume":"274","author":"Zhang","year":"2021","journal-title":"Ann Surg"},{"key":"2025031509021345400_CIT0003","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ccell.2019.04.007","article-title":"Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes","volume":"35","author":"Xue","year":"2019","journal-title":"Cancer Cell"},{"key":"2025031509021345400_CIT0004","doi-asserted-by":"publisher","first-page":"102170","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2025031509021345400_CIT0005","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"Met-dependent solid tumours \u2013 molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025031509021345400_CIT0006","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1634\/theoncologist.2020-0535","article-title":"Identification of a novel EHBP1-MET fusion in an intrahepatic cholangiocarcinoma responding to crizotinib","volume":"25","author":"Yu","year":"2020","journal-title":"Oncologist"},{"key":"2025031509021345400_CIT0007","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025031509021345400_CIT0008","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1200\/jco.2024.42.3_suppl.435","article-title":"Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: results from a randomized proof-of-concept phase II trial (IMbrave151)","volume":"42","author":"El-Khoueiry","year":"2024","journal-title":"JCO"},{"key":"2025031509021345400_CIT0009","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.12998\/wjcc.v10.i8.2529","article-title":"Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: a case report","volume":"10","author":"Liu","year":"2022","journal-title":"World J Clin Cases"},{"key":"2025031509021345400_CIT0010","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1016\/j.jtho.2019.01.025","article-title":"A novel CAV1-MET fusion in SCLC transformation responds to crizotinib and osimertinib treatment","volume":"14","author":"Liu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025031509021345400_CIT0011","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jtho.2017.10.014","article-title":"KIF5B-MET gene rearrangement with robust antitumor activity in response to crizotinib in lung adenocarcinoma","volume":"13","author":"Cho","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025031509021345400_CIT0012","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/nm.4204","article-title":"International Cancer Genome Consortium PedBrain Tumor Project. Recurrent MET\u00a0fusion genes represent a drug target in pediatric glioblastoma","volume":"22","year":"2016","journal-title":"Nat Med"},{"key":"2025031509021345400_CIT0013","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"2025031509021345400_CIT0014","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1158\/1078-0432.CCR-17-3001","article-title":"Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients","volume":"24","author":"Plenker","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025031509021345400_CIT0015","doi-asserted-by":"publisher","first-page":"e16652","DOI":"10.1200\/jco.2020.38.15_suppl.e16652","article-title":"The landscape of met mutations in Chinese biliary tract cancers","volume":"38","author":"Xu","year":"2020","journal-title":"JCO"},{"key":"2025031509021345400_CIT0016","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/oncolo\/oyac194","article-title":"Response to capmatinib in a MET fusion-positive cholangiocarcinoma","volume":"28","author":"Turpin","year":"2023","journal-title":"Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae340\/61018648\/oyae340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae340\/61018648\/oyae340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T09:02:30Z","timestamp":1742029350000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae340\/7920060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae340","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,10]]},"article-number":"oyae340"}}